Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINS: DMT Withdrawal in Inactive RRMS Patients Aged 55+
NCT06663189Phase 3Not yet recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Time to first clinical and/or radiological disease activity at 24 months. Planned start Jan 2025; status: not yet recruiting.
02
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06663189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663189.